

## **Clinical Outcomes of Massive Transfusion Protocols (MTP):** A Comparison of MTP and Targeted MTP in Severe Trauma Patients, Hospital Sungai Buloh (2021–2022)




Chun Chiat Y a, Kiranjit Kaur JS a, Shah Jahan MY a, Rossman Ha, Sarojini M<sup>β</sup> Emergency & Trauma Department, Hospital Sungai Buloh

### Introduction

Massive Transfusion Protocols (MTP) are widely used in trauma resuscitation to deliver red blood cells, plasma, and platelets in fixed ratios. While effective in managing hemorrhage<sup>1</sup>, MTP follows a standardized **approach** that may not reflect individual patient needs<sup>2</sup>.

Targeted MTP (TMTP) offers a more personalized strategy, guided by point-of-care testing to assess coagulation status and tailor transfusion therapy accordingly. At Hospital Sungai Buloh, T-MTP was introduced<sup>3</sup> in early 2022, with activation guided by routine bedside investigations such as full blood count, venous blood gas, and INR to inform transfusion decisions.

This study compares trauma cases managed under MTP (2021-2022) and T-MTP (2022), evaluating clinical outcomes between both groups.




## Methodology

Trauma data were extracted from the Malaysian Trauma Registry. Records were screened to exclude incomplete data, duplicates, and patients under 18, trauma cases treated in Damage Control Resuscitation (DCR) zone from Hospital Sungai Buloh's Emergency Department included.

Patients transfused under MTP (2021-2022) and TMTP (2022) were analyzed. Consent was waived as the study utilized de-identified data extracted from the hospital's trauma registry for secondary analysis.

All statistical analyses were performed using SPSS version 29, comparing clinical variables, transfusion details, and outcomes between groups.



## Result

Age (years)						
Gender (%) 80.0% (Male) 73.1% (Male) 0.631  Mechanism of Injury 90.0% 88.5% 0.845  GCS Total 9.3 ± 4.1 12.3 ± 3.2 0.005  Shock Index (ED arrival) 1.19 ± 0.29 0.97 ± 0.26 0.017  Respiratory Rate (ED) 23.8 ± 5.9 21.1 ± 5.1 0.048  Injury % by Region (mean ± SD) 1.1 ± 8.3 0.243  • Head/Neck 21.7 ± 9.1 19.1 ± 8.3 0.243  • Thorax 24.9 ± 9.8 21.2 ± 8.7 0.204  • Abdomen 18.5 ± 7.5 15.3 ± 6.5 0.138  • Extremities 29.1 ± 10.9 30.6 ± 10.3 0.684  ISS 30.2 ± 8.7 28.3 ± 9.1 0.412  NISS 35.6 ± 9.4 33.1 ± 10.2 0.368  Surgical and Critical Care  Surgery Performed (%) 10	Varia	able	MTP (n=20)	TMTP (n=26)	p-value	
Mechanism of Injury         90.0%         88.5%         0.845           GCS Total         9.3 ± 4.1         12.3 ± 3.2         0.005           Shock Index (ED arrival)         1.19 ± 0.29         0.97 ± 0.26         0.017           Respiratory Rate (ED)         23.8 ± 5.9         21.1 ± 5.1         0.048           Injury % by Region (mean ± SD)         • Head/Neck         21.7 ± 9.1         19.1 ± 8.3         0.243           • Thorax         24.9 ± 9.8         21.2 ± 8.7         0.204           • Abdomen         18.5 ± 7.5         15.3 ± 6.5         0.138           • Extremities /Pelvis         29.1 ± 10.9         30.6 ± 10.3         0.684           ISS         30.2 ± 8.7         28.3 ± 9.1         0.412           NISS         35.6 ± 9.4         33.1 ± 10.2         0.368           Surgical and Critical Care         Surgery         85.0%         69.2%         0.218           ICU Admission (%)         70.0%         61.5%         0.537           Blood products utilisation, Median [IQR]         ICU II-4]         2U [1-4]         2U [1-4]         1U [0-2]           Packed Cell         ICU II-4]         2U [1-4]         2U [1-4]         1U [0-2]         1U [0-2]           Packed Cell         ICU II-4]	Age (years)		41.8 ± 16.9	39.7 ± 17.4	0.612	
Injury	Gender (%)		80.0% (Male)	73.1% (Male)	0.631	
Shock Index (ED arrival)   1.19 ± 0.29   0.97 ± 0.26   0.017     Respiratory Rate (ED)   23.8 ± 5.9   21.1 ± 5.1   0.048     Injury % by Region (mean ± SD)     Head/Neck   21.7 ± 9.1   19.1 ± 8.3   0.243     Thorax   24.9 ± 9.8   21.2 ± 8.7   0.204     Abdomen   18.5 ± 7.5   15.3 ± 6.5   0.138     Extremities   29.1 ± 10.9   30.6 ± 10.3   0.684     ISS   30.2 ± 8.7   28.3 ± 9.1   0.412     NISS   35.6 ± 9.4   33.1 ± 10.2   0.368     Surgical and Critical Care   Surgery Performed (%)   85.0%   69.2%   0.218     ICU Admission (%)   70.0%   61.5%   0.537     Blood products utilisation, Median [IQR]			90.0%	88.5%	0.845	
1.19 ± 0.29   0.97 ± 0.26   0.017	GCS Total		$9.3 \pm 4.1$	$12.3 \pm 3.2$	0.005	
Rate (ED)    17			1.19 ± 0.29	0.97 ± 0.26	0.017	
• Head/Neck 21.7 ± 9.1 19.1 ± 8.3 0.243 • Thorax 24.9 ± 9.8 21.2 ± 8.7 0.204 • Abdomen 18.5 ± 7.5 15.3 ± 6.5 0.138 • Extremities 29.1 ± 10.9 30.6 ± 10.3 0.684  ISS 30.2 ± 8.7 28.3 ± 9.1 0.412  NISS 35.6 ± 9.4 33.1 ± 10.2 0.368  Surgical and Critical Care  Surgery Performed (%) 85.0% 69.2% 0.218  ICU Admission (%) 70.0% 61.5% 0.537  Blood products utilisation, Median [IQR]  MTP 4U [2-6] 4U [2-6] 4U [2-6] 2U [0-2]  TMTP 2U [1-4] 2U [1-4] 2U [1-4] 1U [0-2]  p<0.001 p<0.001 p<0.001 p=0.024  Clinical Outcomes  ICU LOS (days) Hospital Complication (Complication			23.8 ± 5.9	21.1 ± 5.1	0.048	
• Thorax  • Abdomen  • 18.5 ± 7.5  • Extremities  /Pelvis  ISS  30.2 ± 8.7  NISS  35.6 ± 9.4  33.1 ± 10.2  0.368  Surgical and Critical Care  Surgery Performed (%)  ICU Admission (%)  Packed Cell  FFP  Platelet  Platelet  Cyro  MTP  4U [2-6]  4U [2-6]  4U [2-6]  TMTP  2U [1-4]  Pc0.001  Pc0.001  Pc0.001  Pc0.001  Pc0.001  Pc0.001  Pc0.001  Complication  LOS (days)  Complication  LOS (days)  Complication  Complication  LOS (days)	Injury %	6 by Reg	ion (mean ± S	SD)		
• Abdomen 18.5 ± 7.5 15.3 ± 6.5 0.138 • Extremities /Pelvis 29.1 ± 10.9 30.6 ± 10.3 0.684  ISS 30.2 ± 8.7 28.3 ± 9.1 0.412  NISS 35.6 ± 9.4 33.1 ± 10.2 0.368  Surgical and Critical Care  Surgery Performed (%) ICU Admission (%) 70.0% 61.5% 0.537  Blood products utilisation, Median [IQR]  MTP 4U [2-6] 4U [2-6] 4U [2-6] 2U [0-4]  TMTP 2U [1-4] 2U [1-4] 2U [1-4] 1U [0-2]  p<0.001 p<0.001 p<0.001 p<0.001 Complication (days) (days) (days)	• Head/	/Neck	21.7 ± 9.1	19.1 ± 8.3	0.243	
Pelvis    29.1 ± 10.9   30.6 ± 10.3   0.684	• Thorax		$24.9 \pm 9.8$	21.2 ± 8.7	0.204	
Pelvis	• Abdomen		18.5 ± 7.5	$15.3 \pm 6.5$	0.138	
NISS   35.6 ± 9.4   33.1 ± 10.2   0.368			29.1 ± 10.9	30.6 ± 10.3	0.684	
Surgical and Critical Care	ISS		30.2 ± 8.7	28.3 ± 9.1	0.412	
Surgery	NISS		$35.6 \pm 9.4$	33.1 ± 10.2	0.368	
Performed (%)   85.0%   69.2%   0.218     ICU Admission (%)   70.0%   61.5%   0.537     Blood products utilisation, Median [IQR]	Surgica	l and Cı	ritical Care			
MTP   4U   [2-6]   4U   [2-6]   4U   [2-6]   2U   [0-4]     TMTP   2U   [1-4]   2U   [1-4]   1U   [0-2]     p<0.001   p<0.001   p<0.001   p=0.024     Clinical Outcomes   Curvival Rate   LOS (days)   Complication (days)   Complication (days)   Curvival (days)   Complication (days)   Curvival (days)   Complication (days)   Curvival (d			85.0%	69.2%	0.218	
Packed   FFP   Platelet   Cyro		ission	70.0%	61.5%	0.537	
MTP 4U [2-6] 4U [2-6] 4U [2-6] 2U [0-4] TMTP 2U [1-4] 2U [1-4] 2U [1-4] 1U [0-2] p<0.001 p<0.001 p<0.001 p=0.024  Clinical Outcomes  ICU LOS (days) (days)	Blood products utilisation, Median [IQR]					
TMTP 2U [1-4] 2U [1-4] 2U [1-4] 1U [0-2] p<0.001 p<0.001 p=0.024  Clinical Outcomes    Cu			d FFP	Platelet	Cyro	
Clinical Outcomes    Cu	MTP	4U [2-	6] 4U [2-6	6] 4U [2-6]	2U [0-4	
Clinical Outcomes    Cu	TMTP				1U [0-2	
Survival Rate (days)  ICU Hospital Complicatio LOS (days)						
		Surviv	% ICU ral LOS	LOS	Complication	
	MTP	66.7		3 14.2±5.8	25.0%	

#### Discussion

82.6%

**TMTP** 

 TMTP significantly reduced blood products utilization, aligned with findings from an Indian study<sup>4</sup>—while maintaining clinical outcomes.

 $4.9 \pm 2.7$ 

p=0.062

11.6±4.9

p=0.098

13.0%

p=0.379

- A statistically significant improvement in survival was observed in the TMTP group (p = 0.041), suggesting potential benefit of transfusion.
- Although not statistically significant, ICU and hospital stays were shorter by 2-3 days, offering operational advantages<sup>5</sup>.
- Complications as kidney failure, pneumonia, and sepsis were more common in patients receiving higher transfusion volumes<sup>6</sup>.
- Further research is needed to assess blood product wastage, cost-effectiveness, and longterm impact of TMTP.

# Limitation

This is retrospective design, which may introduce selection bias and unmeasured confounders affecting transfusion decisions and outcomes.

#### Conclusion

TMTP is associated with improved survival and reduced blood product usage compared to MTP, while maintaining comparable injury severity and clinical outcomes.

#### Reference 1

Holcomb JB et al. (2015). Transfusion strategies in bleeding trauma patients. Curr Opin Crit Care.

Khan S et al. (2020). Targeted transfusion protocols reduce blood product use in trauma. Transfusion.

- Cotter, S. M., Fazzari, M. J., & Bas, A. (2017). The impact of massive transfusion protocol on trauma patient outcomes. Journal of Trauma and Acute Care Surgery, 82(2), 326-332. Consensus Statement on Patient Blood Management, Ministry of Health, Malaysia, published in March 2024
- Biffl WL, Lu N, Schultz PR, Wang J, Castelo MR, Schaffer KB. Improving length of stay on a trauma service. Trauma Surgery & Acute Care Open. 2021;6(1) Napolitano LM et al. (2011). Complications and outcomes in trauma patients receiving massive transfusion. J Trauma